Compare Cassava Sciences Inc (FLNA) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Shell PLC — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Shell PLC trades at $85.25 (market cap $228.96B). The key difference: Shell PLC is far larger — about 4308.6× Cassava Sciences Inc's market cap, and Shell PLC pays a 3.69% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SHEL | |
|---|---|---|
Market Cap | $53.14M | $228.96B |
Sector | Health | Energy |
52-Week High | $4.64 | $94.15 |
52-Week Low | $1.09 | $70.28 |
Enterprise Value | -$33.43M | $281.49B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Shell (SHEL) trades at $84.41, up 0.51% on the day, with a bullish technical signal and strong analyst support. Recent Q1 2026 earnings beat expectations at $2.44 EPS, though revenue has trended down from $381.3B in 2022 to $266.9B in 2025. The stock shows attractive valuation with a P/E of 13.18 and P/S of 0.93, while news highlights the ARC Resources acquisition approval and Venezuela gas field development plans.
Outlook remains positive given high analyst buy ratings (69%) and a $122.20 consensus price target, but risks include declining operating cash flow, Middle East production disruptions, and exposure to volatile energy markets. Earnings growth and strategic acquisitions are key catalysts for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
